胃がん/胃食道接合部がんに対する三次治療としての抗PD-L1抗体アベルマブ単剤投与の有効性を検証した第Ⅲ相試験JAVELIN Gastric 300の主解析、化学療法との比較でOS、PFSの改善示されず【Ann Oncol】

Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Ann Oncol 2018年7月24日号オンライン版

BACKGROUND:There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase 3 JAVELIN Gastric 300 trial compared avelumab vs physician’s choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*